Skip to content

Application of a small molecule inhibitor screen approach

First, cases with other central nervous system disorders (i

Posted on March 12, 2026 by Courtney Roberts

First, cases with other central nervous system disorders (i.e., tumors, inflammation, Parkinson’s disease, Lewy body disease) were excluded from the present study (n = 194). predominance of AD and vascular pathology in the right hemisphere was associated with significantly higher CDR scores. == Conclusions == Our data show that this Continue Reading

Posted In mGlu Group I Receptors

Categories

  • Activator Protein-1
  • Adenosine A3 Receptors
  • Adenosine, Other
  • AMPA Receptors
  • Amylin Receptors
  • Amyloid Precursor Protein
  • Angiotensin AT2 Receptors
  • AT Receptors, Non-Selective
  • CaM Kinase Kinase
  • Carbohydrate Metabolism
  • Catechol O-methyltransferase
  • COMT
  • DNA, RNA and Protein Synthesis
  • Dopamine Transporters
  • Dopaminergic-Related
  • DPP-IV
  • Endopeptidase 24.15
  • Exocytosis
  • F-Type ATPase
  • FAK
  • GLP2 Receptors
  • H2 Receptors
  • H4 Receptors
  • I??B Kinase
  • I1 Receptors
  • Inositol Monophosphatase
  • Isomerases
  • Leukotriene and Related Receptors
  • mGlu Group I Receptors
  • Mre11-Rad50-Nbs1
  • MRN Exonuclease
  • Muscarinic (M5) Receptors
  • N-Methyl-D-Aspartate Receptors
  • Neuropeptide FF/AF Receptors
  • NO Donors / Precursors
  • Other Proteases
  • Other Reductases
  • PKA
  • Platelet Derived Growth Factor Receptors
  • Polyamine Synthase
  • Protease-Activated Receptors
  • PrP-Res
  • Reagents
  • Reductase, 5??-
  • Selectins
  • Serotonin (5-HT1) Receptors
  • Tau
  • trpml
  • Tryptophan Hydroxylase
  • Urokinase-type Plasminogen Activator

Recent Posts

  • In 2007, Racil et approach
  • These glycosylases excise a broken base producing an abasic site that is converted to a single nucleotide space by AP endonuclease
  • L
  • Yet , vaccines ought to be reformulated annually owing to the rapid virus-like antigenic progress (Plotkin tout autant que al
  • The final decade indicates that there is a previously unrecognized variability among BoNT molecules: the serotypes A, M, E, and F can be distinguished into more than forty five subtypes based on their alanine sequence, antibody binding and functional activity
Copyright All rights reserved. Theme: Flash Blog by Unitedtheme.